BioEclipse Therapeutics focuses on developing immunotherapies for cancer treatment, specifically targeting solid tumors and enhancing patient responses through combined therapies involving immune cells and oncolytic viruses. The company is currently advancing its product, CRX100, through clinical trials.

BioEclipse Therapeutics

ElevateBio is a technology-driven genetic medicines company, accelerating access to cutting-edge technologies, end-to-end manufacturing capabilities, and expertise to advance the cell and gene therapy industry. The company's integrated ecosystem of technologies and capabilities enables the discovery, development, manufacturing, and commercialization of a broad spectrum of cell and gene therapies and regenerative medicines.

Clare Murray

ElevateBio

Affimed is a clinical-stage biopharmaceutical company focused on developing cancer immunotherapies using its ROCK® (Redirected Optimized Cell Killing) platform.

Affimed

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts.

Metric
Company Name	BioEclipse Therapeutics	ElevateBio	Affimed	Genocea Biosciences, Inc.
Symbol				GNCA
MSH ID	COM:BIOECLIPSE	BIO:ELEVATE	COM:AFFIMED	COM:GENOCEA
Market	PRIVATE	PRIVATE	PRIVATE	STOCKS
Sector	Healthcare & Health Services	Healthcare & Health Services	Healthcare & Health Services
Industry	Biotechnology	Biotechnology	Biotechnology
Country	US	US	DE	US
Stage		Series D
Employee Count		462	105	74
Website	bioeclipse.com	elevate.bio	affimed.com	genocea.com
LinkedIn		elevatebio	affimed-ag
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic		7.15K
Web Traffic Growth		-0.51
Valuation
Raised Capital		401M

Metric
Revenue				1.64M
Revenue (LTM)
Revenue (NTM)
Gross Profit				1.64M
EBITDA				-34.32M
Operating Income				-52.09M
Net Income				-15.42M
EPS				-0.22
Diluted EPS				-0.22
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin				1
Operating Profit Margin				-31.74
EBITDA Margin				-20.91
Net Profit Margin				-9.40
Return on Equity				-0.86
Return on Assets				-0.28
Return on Capital Employed				-1.40

BIOE

COM:BIOECLIPSE

BioEclipse Therapeutics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio				-0.00
P/B Ratio				0.00
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple				-0.76

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover				0.03

Metric
Operating Cash Flow				-45.37M
Free Cash Flow				-48.66M
Cash Flow to Debt				-4.08
Operating Cash Flow/Sales				-27.65
Free Cash Flow Yield

Metric
Cash & Equivalents				37.15M
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization				0.29
Debt to Assets				0.20
Current Ratio				2.24
Quick Ratio				1.99

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue				23.78
SG&A to Revenue				8.97